- Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
-
Kim D, Kim W, Ahmed A
- KMID: 2563412
- Clin Mol Hepatol.
- 2025 Jan;31(1):e5-e7.
- doi: 10.3350/cmh.2024.0849
-
- CITED
-
- Close
- SHARE
-
- Close
- Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
-
Nishida N
- KMID: 2563438
- Clin Mol Hepatol.
- 2025 Jan;31(1):311-315.
- doi: 10.3350/cmh.2024.0739
-
- CITED
-
- Close
- SHARE
-
- Close
- TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
-
Caddeo A, Mancina RM
- KMID: 2563433
- Clin Mol Hepatol.
- 2025 Jan;31(1):293-296.
- doi: 10.3350/cmh.2024.0703
-
- CITED
-
- Close
- SHARE
-
- Close
- Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models
-
Zhang Z, Wu G
- KMID: 2563413
- Clin Mol Hepatol.
- 2025 Jan;31(1):e8-e9.
- doi: 10.3350/cmh.2024.0958
-
- CITED
-
- Close
- SHARE
-
- Close
- Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
-
Bertoletti A, Tan AT
- KMID: 2563478
- Clin Mol Hepatol.
- 2025 Jan;31(1):e113-e116.
- doi: 10.3350/cmh.2024.0867
-
- CITED
-
- Close
- SHARE
-
- Close
- Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”
-
Marco S, Braconi C
- KMID: 2563441
- Clin Mol Hepatol.
- 2025 Jan;31(1):323-326.
- doi: 10.3350/cmh.2024.0932
-
- CITED
-
- Close
- SHARE
-
- Close
- Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma
-
Shen X, Wu J
- KMID: 2563446
- Clin Mol Hepatol.
- 2025 Jan;31(1):e17-e18.
- doi: 10.3350/cmh.2024.0794
-
- CITED
-
- Close
- SHARE
-
- Close
- Reply to correspondence on “Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK”
-
Baek YH
- KMID: 2563482
- Clin Mol Hepatol.
- 2025 Jan;31(1):e123-e124.
- doi: 10.3350/cmh.2024.0966
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
-
Feng W, Wang Q, Ye Q
- KMID: 2563448
- Clin Mol Hepatol.
- 2025 Jan;31(1):e21-e22.
- doi: 10.3350/cmh.2024.0887
-
- CITED
-
- Close
- SHARE
-
- Close
- Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
-
Li XS, Shen XP, Li H
- KMID: 2563445
- Clin Mol Hepatol.
- 2025 Jan;31(1):e15-e16.
- doi: 10.3350/cmh.2024.0784
-
- CITED
-
- Close
- SHARE
-
- Close
- Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
-
Kanzaki H, Hoshida Y
- KMID: 2563437
- Clin Mol Hepatol.
- 2025 Jan;31(1):308-310.
- doi: 10.3350/cmh.2024.0726
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
-
Cho Y, Jun DW
- KMID: 2563474
- Clin Mol Hepatol.
- 2025 Jan;31(1):e103-e104.
- doi: 10.3350/cmh.2024.0818
-
- CITED
-
- Close
- SHARE
-
- Close
- Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
-
Lee SK, Choi JY
- KMID: 2563435
- Clin Mol Hepatol.
- 2025 Jan;31(1):301-303.
- doi: 10.3350/cmh.2024.0716
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”
-
Zhang R, Wei D, Chen Z, Bian H
- KMID: 2563459
- Clin Mol Hepatol.
- 2025 Jan;31(1):e58-e60.
- doi: 10.3350/cmh.2024.0590
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to editorial on: “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
-
Sharma SP, Suk KT
- KMID: 2563464
- Clin Mol Hepatol.
- 2025 Jan;31(1):e74-e77.
- doi: 10.3350/cmh.2024.0872
-
- CITED
-
- Close
- SHARE
-
- Close
- The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study”
-
Kim SS, Cheong JY
- KMID: 2563439
- Clin Mol Hepatol.
- 2025 Jan;31(1):316-318.
- doi: 10.3350/cmh.2024.0847
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
-
Hur MH, Kim YJ
- KMID: 2563470
- Clin Mol Hepatol.
- 2025 Jan;31(1):e93-e95.
- doi: 10.3350/cmh.2024.0943
-
- CITED
-
- Close
- SHARE
-
- Close
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
-
Meda C, Dolce A, Torre SD
- KMID: 2563442
- Clin Mol Hepatol.
- 2025 Jan;31(1):327-332.
- doi: 10.3350/cmh.2024.0419
-
- CITED
-
- Close
- SHARE
-
- Close
- The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
-
Wang Z, Wan D, Xu M, Jiang Y
- KMID: 2563450
- Clin Mol Hepatol.
- 2025 Jan;31(1):e25-e26.
- doi: 10.3350/cmh.2024.0993
-
- CITED
-
- Close
- SHARE
-
- Close
- From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023”
-
Argirion I
- KMID: 2563431
- Clin Mol Hepatol.
- 2025 Jan;31(1):286-289.
- doi: 10.3350/cmh.2024.0597
-
- CITED
-
- Close
- SHARE
-
- Close
